AN2 Therapeutics Inc. (ANTX)
AN2 Therapeutics Statistics
Share Statistics
AN2 Therapeutics has 30.1M shares outstanding. The number of shares has increased by 0.9% in one year.
| Shares Outstanding | 30.1M |
| Shares Change (YoY) | 0.9% |
| Shares Change (QoQ) | 0.74% |
| Owned by Institutions (%) | 48.69% |
| Shares Floating | 19.82M |
| Failed to Deliver (FTD) Shares | 3.66K |
| FTD / Avg. Volume | 2.78% |
Short Selling Information
The latest short interest is 133.57K, so 0.45% of the outstanding shares have been sold short.
| Short Interest | 133.57K |
| Short % of Shares Out | 0.45% |
| Short % of Float | 0.64% |
| Short Ratio (days to cover) | 0.82 |
Valuation Ratios
The PE ratio is 0 and the forward PE ratio is -1.06. AN2 Therapeutics's PEG ratio is 0.
| PE Ratio | 0 |
| Forward PE | -1.06 |
| PS Ratio | 0 |
| Forward PS | 0.1 |
| PB Ratio | 0 |
| P/FCF Ratio | 0 |
| PEG Ratio | 0 |
Enterprise Valuation
Currently the Enterprise Value (EV) is not available for AN2 Therapeutics.
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 8.43, with a Debt / Equity ratio of 0.
| Current Ratio | 8.43 |
| Quick Ratio | 8.43 |
| Debt / Equity | 0 |
| Debt / EBITDA | 0 |
| Debt / FCF | 0 |
| Interest Coverage | 0 |
Financial Efficiency
Return on Equity is n/a and Return on Invested Capital is n/a.
| Return on Equity | n/a |
| Return on Assets | n/a |
| Return on Invested Capital | n/a |
| Revenue Per Employee | $0 |
| Profits Per Employee | $-2.94M |
| Employee Count | 22 |
| Asset Turnover | null |
| Inventory Turnover | n/a |
Taxes
| Income Tax | 0 |
| Effective Tax Rate | 0% |
Stock Price Statistics
The stock price has increased by -58.82% in the last 52 weeks. The beta is 0.14, so AN2 Therapeutics's price volatility has been higher than the market average.
| Beta | 0.14 |
| 52-Week Price Change | -58.82% |
| 50-Day Moving Average | 1.25 |
| 200-Day Moving Average | 1.44 |
| Relative Strength Index (RSI) | 55.25 |
| Average Volume (20 Days) | 131.88K |
Income Statement
| Revenue | n/a |
| Gross Profit | 0 |
| Operating Income | -69.64M |
| Net Income | -64.73M |
| EBITDA | 4.9M |
| EBIT | -64.73M |
| Earnings Per Share (EPS) | -2.74 |
Balance Sheet
The company has 21.35M in cash and 0 in debt, giving a net cash position of 21.35M.
| Cash & Cash Equivalents | 21.35M |
| Total Debt | 0 |
| Net Cash | 21.35M |
| Retained Earnings | -205.78M |
| Total Assets | 92.09M |
| Working Capital | 76.02M |
Cash Flow
In the last 12 months, operating cash flow was -49.26M and capital expenditures 0, giving a free cash flow of -49.26M.
| Operating Cash Flow | -49.26M |
| Capital Expenditures | 0 |
| Free Cash Flow | -49.26M |
| FCF Per Share | 0 |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
ANTX does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | n/a |
| FCF Yield | n/a |
Analyst Forecast
The average price target for ANTX is $5, which is 257.1% higher than the current price. The consensus rating is "Hold".
| Price Target | $5 |
| Price Target Difference | 257.1% |
| Analyst Consensus | Hold |
| Analyst Count | 5 |
Scores
| Altman Z-Score | -1.72 |
| Piotroski F-Score | 2 |